JP2023532917A5 - - Google Patents

Info

Publication number
JP2023532917A5
JP2023532917A5 JP2022581341A JP2022581341A JP2023532917A5 JP 2023532917 A5 JP2023532917 A5 JP 2023532917A5 JP 2022581341 A JP2022581341 A JP 2022581341A JP 2022581341 A JP2022581341 A JP 2022581341A JP 2023532917 A5 JP2023532917 A5 JP 2023532917A5
Authority
JP
Japan
Prior art keywords
cells
cell
recombinant
gene
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022581341A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532917A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/039953 external-priority patent/WO2022006309A1/en
Publication of JP2023532917A publication Critical patent/JP2023532917A/ja
Publication of JP2023532917A5 publication Critical patent/JP2023532917A5/ja
Pending legal-status Critical Current

Links

JP2022581341A 2020-07-03 2021-06-30 B細胞のb2m遺伝子座を編集するための方法および組成物 Pending JP2023532917A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063047978P 2020-07-03 2020-07-03
US63/047,978 2020-07-03
US202063114131P 2020-11-16 2020-11-16
US63/114,131 2020-11-16
PCT/US2021/039953 WO2022006309A1 (en) 2020-07-03 2021-06-30 Methods and compositions for editing the b2m locus in b cells

Publications (2)

Publication Number Publication Date
JP2023532917A JP2023532917A (ja) 2023-08-01
JP2023532917A5 true JP2023532917A5 (cg-RX-API-DMAC10.html) 2024-07-04

Family

ID=79315579

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022581341A Pending JP2023532917A (ja) 2020-07-03 2021-06-30 B細胞のb2m遺伝子座を編集するための方法および組成物

Country Status (10)

Country Link
EP (1) EP4175651A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023532917A (cg-RX-API-DMAC10.html)
KR (1) KR20230035048A (cg-RX-API-DMAC10.html)
CN (1) CN116033910A (cg-RX-API-DMAC10.html)
AU (1) AU2021300358A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022026534A2 (cg-RX-API-DMAC10.html)
CA (1) CA3186620A1 (cg-RX-API-DMAC10.html)
IL (1) IL299491A (cg-RX-API-DMAC10.html)
MX (1) MX2022015788A (cg-RX-API-DMAC10.html)
WO (1) WO2022006309A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023187779A1 (en) * 2022-03-28 2023-10-05 Ramot At Tel-Aviv University Ltd. Site-specific in vivo t cell engineering, systems, compositions and methods thereof
EP4565716A4 (en) * 2022-08-01 2026-07-15 Idexx Lab Inc FRACTIONAL ABUNDANCE DOSES OF HUMAN MOUSE
KR20250175332A (ko) * 2023-04-17 2025-12-16 비이 바이오파마, 인크. 혈우병 치료를 위한 조작된 세포 제제
CN120866304A (zh) * 2024-04-23 2025-10-31 南京奇迹生物科技有限公司 对b2m基因座的基因编辑方法
KR102955030B1 (ko) * 2025-11-04 2026-04-23 대한민국 신규한 가이드 rna 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073955A2 (en) * 2014-11-06 2016-05-12 President And Fellows Of Harvard College Cells lacking b2m surface expression and methods for allogeneic administration of such cells
AU2016374253B2 (en) * 2015-12-18 2021-10-21 Sangamo Therapeutics, Inc. Targeted disruption of the MHC cell receptor
AU2018292181B2 (en) * 2017-06-30 2025-04-10 Cellectis Cellular immunotherapy for repetitive administration
SG11202004529XA (en) * 2017-11-16 2020-06-29 Mogam Inst Biomedical Res Transformed human cell and use thereof
US12378572B2 (en) * 2018-09-07 2025-08-05 Crispr Therapeutics Ag Universal donor cells
AU2019341365A1 (en) * 2018-09-21 2021-05-27 Crage Medical Co., Limited Method for gene editing of cell on the basis of CRISPR/Cas system
UY38427A (es) * 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares

Similar Documents

Publication Publication Date Title
JP7194230B2 (ja) クローディン-18.2-特異的免疫受容体およびt細胞エピトープ
JP6538622B2 (ja) ホモ二量体タンパク質コンストラクト
EP3511413B1 (en) Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
KR20230172630A (ko) 종양 네오 항원성 펩타이드
JP2020509780A5 (cg-RX-API-DMAC10.html)
JP2021168662A (ja) 免疫グロブリンの産生増強
US20150218260A1 (en) Interleukin-2 fusion proteins and uses thereof
RU2019119272A (ru) Вирусная доставка неоантигенов
JP2024519515A5 (cg-RX-API-DMAC10.html)
KR20230172047A (ko) 종양 신생항원 펩타이드 및 이의 용도
RS61387B2 (sr) Gen optimizovanog faktora viii
KR20240006721A (ko) 막 형질 전환 네오 안티젠 펩타이드
Kroczek et al. Structure-function relationship of XCL1 used for in vivo targeting of antigen into XCR1+ dendritic cells
JP2023532917A (ja) B細胞のb2m遺伝子座を編集するための方法および組成物
JP2023526587A (ja) 改変型上皮成長因子受容体及び細胞追跡におけるその使用
TW201124535A (en) SORF constructs and multiple gene expression
Boulanger et al. Absence of tapasin alters immunodominance against a lymphocytic choriomeningitis virus polytope
WO2020219504A1 (en) Modulating survival of therapeutic cells and methods, cells and nucleic acids related thereto
Simpson et al. FcγRIIB (CD32B) antibodies enhance immune responses through activating FcγRs
CN1511163A (zh) 抗体制备与筛选方法
KR20250021382A (ko) 바이러스 펩티드 및 이의 용도
US12162925B2 (en) DNA-encoded monoclonal antibodies targeting the Ebolavirus glycoprotein
CN1194089C (zh) 大胡蜂镇静肽前体基因及其编码的多肽和制备方法
KR20060135280A (ko) 선천성 면역에 관여하는 트렘-2의 클로닝
EP4501954A1 (en) A nucleic acid encoding a cd8 alpha beta co-receptor, cells and pharmaceutical compositions comprising the same